Market Scope
Market Research Future (MRFR) The Amyotrophic Lateral Sclerosis Market is expected to reach USD 1.08 billion at 6.10% CAGR during the forecast period 2022-2030
Major Boosters Deterrents
The amyotrophic lateral sclerosis industry will benefit from the mounting demand for innovative IT solutions that facilitate efficient value-based healthcare delivery. Massive investments in the upgradation of healthcare infrastructure, and the rampant requirement for effective disease management could have a remarkable impact on the worldwide market in subsequent years. A vital growth inducing factor can be the alarming surge in ASL cases worldwide, bolstering the need for advanced treatments as well as drugs.
Large-scale RD expenditure for better quality drugs and treatments combined with the fast- expanding medical tourism industry in developing countries like India will offer attractive opportunities to the vendors operating in the global industry. The surge in government involvement in the field in terms of funding and new initiatives could further enhance the industry share in the following years.
Market Segmentation
Type, treatment type, and end-users are the key segments considered in the Amyotrophic Lateral Sclerosis Market Insights study.
Amyotrophic lateral sclerosis types covered in the extensive study are sporadic as well as familial. Over the analysis timeframe, the global market will be led by sporadic ALS, or SALS.
In the amyotrophic lateral sclerosis industry, the types of treatment include physical therapy, medication, speech therapy, respiratory therapy, and more. Out of these treatments, the lead has been achieved by the medication segment in the market.
End-users in the amyotrophic lateral sclerosis industry are research academic institutions, specialty centers, hospitals, and others. Hospitals form the biggest segment, says MRFR.
Regional Status
MRFR projects the American market to reign over the worldwide Amyotrophic Lateral Sclerosis Market Outlook, thanks to the rapidly surging awareness about the condition and the rise in hypertension cases. Substantial healthcare spending, supportive reimbursement policies, escalating demand for novel ALS drugs, and well-developed healthcare infrastructure foster the market size to a large extent. Numerous initiatives are being set up by the government, several authoritative bodies as well as the Collaborative ALS Drug Discovery Initiative, focused on fast-tracking the development of treatments and drugs.
The amyotrophic lateral sclerosis industry in Europe has secured the second position, resulting from the highly developed healthcare sector and a well-established infrastructure. Many of the healthcare organizations are focused on setting up research centers for ALS, spending considerably to foster their efforts in the field. Online pharmacies have gained a lot of prominence in the region, in view of the mounting popularity of various eCommerce channels that provide extensive lines of medicines as well as drug information.
Top Firms
ITF Pharma (U.S.), Ascend Pharmaceuticals LLC (U.S.), Biogen (U.S.), Ionis Pharmaceutical (U.S.), Mylan N.V. (U.S.), Sun Pharmaceutical (India), Sanofi (France), Apotex Inc. (Canada), Mitsubishi Tanabe Pharma America (U.S.), Covis Pharma (Switzerland) are the major Amyotrophic Lateral Sclerosis Market Players developers outlined in the report. Asia Pacific will be the most rapidly expanding market in the future, as the number of generic drug manufacturers continues to soar in the region, particularly in China and India. The regional industry further benefits from the rise in RD spending by the healthcare industry, surge in unmet medical requirements, and promising efforts by the local manufacturers to promote their brands.
Latest Updates
- December 2021
BrainStorm Cell Therapeutics Inc., a well-known manufacturer of cellular therapies focused on neurodegenerative diseases, has joined hands with Catalent, a world-renowned name in the cell, biopharma, gene and consumer health space, for the technology transfer of the NurOwn production at Catalent's unit. BrainStorm-owned NurOwn is a nautologous cellular therapy that could help treat amyotrophic lateral sclerosis (ALS), along with progressive multiple sclerosis (PMS) and various neurodegenerative disorders.
- December 2021
Amydis confirms its intention to start with a clinical study in 2022 to assess the potential of its small molecule tracer for the detection of toxic TDP-43 clumps, amyotrophic lateral sclerosis’ hallmark, present in the retina.
Related Report:
Periodontal Therapeutic Market Research Report – Forecast to 2027
Smart Pills Market Research Report - Forecast to 2027
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
Contact:
Market Research Future®
99 Hudson Street,5Th Floor
New York, New York 10013
United States of America
Phone:
+1 628 258 0071(US)
+44 2035 002 764(UK)
